This May, Infigratinib (TRUSELTIQ) received approval by the FDA for adults treatment of cholangiocarcinoma.

It is an ATP-competitive, fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3) tyrosine kinase inhibitor implicated in origin of FGFR-driven diseases.


Infigratinib contains dihalogen dimethoxy aniline moiety in its backbone.


We have made a set of Building Blocks, which contain similar parts – the perfect start for your research!